ArticleAlimentary pharmacology & therapeutics2013
Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.
Article in Alimentary pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 105 citations in OpenAlex.
- Trial
- Trial
- Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.Diabetologia · 2017Trial
- Use of serum levels of proinflammatory cytokine IL-1alpha in chronic hepatitis B.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2014Trial
- [Novel advances following the integration of Baveno VII consensus definitions for the non-invasive testing of portal hypertension].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Biomarkers of Extracellular Matrix Remodelling Are Linked to Severity and Outcome of Advanced Chronic Liver Disease.Alimentary pharmacology & therapeutics · 2026Article
- When new therapies arrive, we should think more: The unseen challenges of immunotherapy-induced remodeling.World journal of clinical cases · 2025Article
- Splenectomy and risk of hepatocellular carcinoma.World journal of hepatology · 2025Review
- The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects.Biomedicines · 2025Review
- Use of Noninvasive Tests to Assess Clinically Significant Portal Hypertension and Response to Beta-Blockers.Gastro hep advances · 2025Review
- Standard technique in Japan for measuring hepatic venous pressure gradient.Journal of gastroenterology · 2025Review
- Non-Invasive Diagnostic Tests for Portal Hypertension in Patients with HBV- and HCV-Related Cirrhosis: A Comprehensive Review.Medicina (Kaunas, Lithuania) · 2024Review
- PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.JHEP reports : innovation in hepatology · 2023Article
- Role of elastic fiber degradation in disease pathogenesis.Biochimica et biophysica acta. Molecular basis of disease · 2023Review
- Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV.BMC infectious diseases · 2023Article
- Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease.Liver international : official journal of the International Association for the Study of the Liver · 2022Article
- Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation.Alimentary pharmacology & therapeutics · 2021Article
- Serum C-reactive protein metabolite (CRPM) is associated with incidence of contralateral knee osteoarthritis.Scientific reports · 2021Article
- Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease.JHEP reports : innovation in hepatology · 2021Article
- Regression of portal hypertension: underlying mechanisms and therapeutic strategies.Hepatology international · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe hepatic venous pressure gradient (HVPG) is an invasive, but important diagnostic and prognostic marker in cirrhosis with portal hypertension (PHT). During cirrhosis, remodelling of fibrotic tissue by matrix metalloproteinases (MMPs) is a permanent process generating small fragments of degraded extracellular matrix (ECM) proteins known as neoepitopes, which are then released into the circulation.
aimTo investigate their potential as plasma markers for detection of PHT.
methodsNinety-four patients with alcoholic cirrhosis and 20 liver-healthy controls were included. Clinical and laboratory data of the patients were collected. All patients received HVPG measurement with blood sampling. In these samples, the following degradation or formation markers were measured: C1M (type I-collagen), C3M and PRO-C3 (type III collagen), C4M and P4NP 7S (type IV collagen), C5M (type V collagen), C6M (type VI collagen), BGM (biglycan), ELM (elastin), CRPM (CRP).
resultsAll ECM markers except for CRPM correlated significantly with HVPG. Interestingly, C4M, C5M and ELM levels were significantly higher in patients with HVPG >10 mmHg. Multiple regression analysis identified PRO-C3, C6M and ELM as significant determinants, while the models A and B including PRO-C3, ELM, C6M and model for end-stage liver disease (MELD) provided better description of PHT (r = 0.75, P < 0.0001). The models provided odds ratios of >100 for having clinical significant PHT.
conclusionsThese novel non-invasive extracellular matrix markers reflect the degree of liver dysfunction. The different degrees of portal hypertension correlated with these circulating neoepitopes. Using a single blood sample, these neoepitopes in combination with MELD detect the level of portal hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.